Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review.
ICIs
alectinib
anti-PD-1 antibody
severe skin toxicity
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
23
11
2021
medline:
7
6
2022
entrez:
22
11
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell lung cancer (NSCLC). Alectinib is said to be safer than other TKIs. We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. These findings suggest that we should carefully follow patients for adverse effects of targeted drugs following ICI treatment.
Identifiants
pubmed: 34803090
doi: 10.2169/internalmedicine.7472-21
pmc: PMC9259316
doi:
Substances chimiques
Carbazoles
0
Piperidines
0
Protein Kinase Inhibitors
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
alectinib
LIJ4CT1Z3Y
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1735-1738Références
Ann Oncol. 2019 May 1;30(5):839-844
pubmed: 30847464
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
SAGE Open Med Case Rep. 2020 Oct 24;8:2050313X20966895
pubmed: 33149916
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
Transl Lung Cancer Res. 2021 Jan;10(1):314-325
pubmed: 33569315
Case Rep Oncol. 2016 Dec 8;9(3):826-832
pubmed: 28101031
Onco Targets Ther. 2015 Jun 03;8:1321-5
pubmed: 26082648
Lung Cancer. 2016 Sep;99:66-8
pubmed: 27565916
J Oncol Pharm Pract. 2020 Dec;26(8):2028-2030
pubmed: 32476587
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051